Form 8-K - Current report:
SEC Accession No. 0001193125-25-008461
Filing Date
2025-01-17
Accepted
2025-01-17 16:41:26
Documents
14
Period of Report
2025-01-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d909443d8k.htm   iXBRL 8-K 25747
2 EX-10.1 d909443dex101.htm EX-10.1 211768
  Complete submission text file 0001193125-25-008461.txt   412957

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA alxo-20250116.xsd EX-101.SCH 2862
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE alxo-20250116_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alxo-20250116_pre.xml EX-101.PRE 10820
17 EXTRACTED XBRL INSTANCE DOCUMENT d909443d8k_htm.xml XML 3550
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

EIN.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39386 | Film No.: 25539216
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)